Skip to main content
Research
Research

Aplin Research

Contact

Andrew Aplin, PhD
  • Deputy Director, Sidney Kimmel Comprehensive Cancer Center
  • Kalbach-Newton Professor in Cancer Research
Department of Pharmacology, Physiology & Cancer Biology

233 S 10th Street
BLSB 1050
Philadelphia, PA 19107

Publications

Recent Publications

FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma

Meeting Report From the 2023 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Philadelphia, PA, November 2023

Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma

SOX10 Loss Sensitizes Melanoma Cells to Cytokine-Mediated Inflammatory Cell Death

Slow proliferation of BAP1-deficient uveal melanoma cells is associated with reduced S6 signaling and resistance to nutrient stress

Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma

High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma

Targeting TEAD-ious resistance

Gene signature reveals decreased SOX10-dependent transcripts in malignant cells from immune checkpoint inhibitor-resistant cutaneous melanomas

Targeting up-regulated cIAP2 in SOX10-deficient drug tolerant melanoma

MacroH2A restricts inflammatory gene expression in melanoma cancer-associated fibroblasts by coordinating chromatin looping

Site matters in metastatic melanoma

Co-Targeting FASN and mTOR Suppresses Uveal Melanoma Growth

Lysosomal lipid peroxidation regulates tumor immunity

Engaging community members in cancer research: an assessment of an NCI-designated cancer center

IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression

Raptinal Induces Gasdermin E-Dependent Pyroptosis in Naïve and Therapy-Resistant Melanoma

Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma

Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p/PD-L1 pathway

The future of targeted kinase inhibitors in melanoma

Lysine Methyltransferase NSD1 and Cancers: Any Role in Melanoma?

Multi-omics Profiling Shows BAP1 Loss Is Associated with Upregulated Cell Adhesion Molecules in Uveal Melanoma

A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in NRAS Mutant Melanoma

Packing a Punch against PD-L1

Pyruvate dehydrogenase inactivation causes glycolytic phenotype in BAP1 mutant uveal melanoma

Publications

Scopus Feed has no publications.

Go Back to Aplin Research